Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of Sulfated Mannoglucuronide Hexasaccharide in Prevention and Treatment of Atherosclerosis

A technology for atherosclerosis and uronic acid hexasaccharide, applied in the prevention and treatment of atherosclerosis, in the field of sulfated mannose glucuronic acid hexasaccharide, which can solve the problems such as the application of sulfated mannose glucuronic acid oligosaccharide , to achieve the effect of inhibiting absorption effect and small toxic side effects

Active Publication Date: 2021-02-12
ZHEJIANG HOSPITAL
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no information on the application of sulfated mannoglucuronide oligosaccharides in the treatment of atherosclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Sulfated Mannoglucuronide Hexasaccharide in Prevention and Treatment of Atherosclerosis
  • Application of Sulfated Mannoglucuronide Hexasaccharide in Prevention and Treatment of Atherosclerosis
  • Application of Sulfated Mannoglucuronide Hexasaccharide in Prevention and Treatment of Atherosclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056]Example 1 Preparation of sulfated mannose glucuronic acid hexaose

[0057]1. Preparation of mannose glucuronic acid oligosaccharides

[0058]The dried kelp was extracted with 30 times the mass of distilled water at 100°C for 3 hours. The extract was filtered and concentrated. After concentration, ethanol was added to the final concentration of 75% to precipitate. After standing for 12 hours, the precipitate was collected, and then dried in vacuum to obtain kelp polysaccharide. . The kelp polysaccharide sample was dissolved in a sulfuric acid solution with a mass concentration of 4% (the material-to-liquid ratio was 60mg / mL) and heated to reflux for 5 hours, neutralized with barium hydroxide to pH=6-7, centrifuged, and the supernatant was concentrated to the original One-fifth of the volume, the concentrate is chromatographed on activated carbon column, first equilibrated with distilled water, and then eluted with a gradient of 50%-90% ethanol, and the 50%-90% ethanol eluate is conce...

Embodiment 2

[0065]Example 2 Regulation of Sulfated Mannoglucuronic Acid Hexose on Inflammatory Factors

[0066]Inoculate THP-1 cells in a 6-well plate (4×105Cells / well, RPMI-1640 complete culture medium containing 10% FBS), add phorbol ester (PMA) at a final concentration of 100ng / ml, and continue to culture for 48h to induce monocytes to differentiate into macrophages. The experimental group was added 0.25mg / ml, 0.5mg / ml, 1mg / ml sulfated mannoglucuronic acid hexaose. Incubate for 48 hours, collect the culture solution, and remove the precipitate at 4000 rpm for 5 min. ELISA kit detects the release levels of TNF-α and IL-1β.

[0067]The result isfigure 1 As shown, sulfated mannose glucuronide hexaose at a concentration of 0.5 mg / ml can significantly reduce the inflammatory factor TNF-α (figure 1 A) and IL-1β (figure 1 The expression level of B) is increased to 1 mg / ml, and the effect of reducing the expression level of inflammatory factors is more obvious than that of the 0.5 mg / ml group, showing a c...

Embodiment 3

[0068]Example 3 Inhibitory regulation of sulfated mannoglucuronic acid hexaose on NF-κB signaling pathway

[0069]Inoculate THP-1 cells in a 60mm culture dish (2×106Cells / well, RPMI-1640 complete culture medium containing 10% FBS), add phorbol ester (PMA) at a final concentration of 100ng / ml, and continue to culture for 48h to induce monocytes to differentiate into macrophages. The experimental group was added 0.5mg / ml and 1mg / ml sulfated mannose glucuronic acid hexaose. Incubate for 48 hours, remove the medium, wash with PBS, add 100 μL of RIPA lysis buffer containing protease and phosphatase inhibitors, scrape the cells with a cell scraper, and transfer the cell lysate to a 1.5 mL EP tube to lyse the cells on ice for 30 minutes; 4 Centrifuge at 13000 rpm for 15 min at ℃, and transfer the supernatant to a new 1.5 mL EP tube. Use the BCA protein concentration determination kit for concentration determination, and store in -80℃ refrigerator. Western blot was used to detect the molecular...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of sulfated mannoglucuronic acid hexasaccharide in preventing and treating atherosclerosis. The invention discloses that sulfated mannoglucuronide oligosaccharides can effectively inhibit the inflammatory factors in macrophages related to atherosclerosis and the absorption effect of macrophages on oxidized low-density lipoprotein, thereby contributing to the development of atherosclerosis The prevention and treatment of sclerosis provide new means.

Description

Technical field[0001]The invention belongs to the technical fields of medicinal chemistry and medicine, and relates to the application of sulfated mannose glucuronic acid hexaose in the prevention and treatment of atherosclerosis.Background technique[0002]Atherosclerotic cardiovascular disease (ASCVD) has become the first cause of death in humans (Smith S J. Adherence to Medical Therapy and the Global Burden of Cardiovascular Disease[J].J Am Coll Cardiol.2016,67 (13):1516-1518.). So far, no effective measures have been found to further reduce the cardiovascular residual risk of ASCVD patients (Colantonio LD, Bittner V. Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels[J]. Endocrinol Metab Clin North Am. 2016, 45(1) :171-184). The reason lies in the complexity of the mechanism of atherosclerosis (AS). Macrophages play a pivotal role in the occurrence and development of AS. Macrophages take up oxidized low-density lipoprotein (Oxidized lo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/737A61P9/10A61P29/00
CPCA61K31/737A61P9/10A61P29/00
Inventor 暴一众金维华毛根祥王继荣吴万里王三应刘小伟张文静
Owner ZHEJIANG HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com